«

»

Oct 06

I agree that a extravesicle approach in this setting in this setting.

The group concluded that extravesical ureteral reimplantation without difficulty by dextranomer / hyaluronic acid implantation failure are carried out and seems to be an excellent treatment option. I agree that a extravesicle approach in this setting in this setting, and in experienced hands can be laparoscopically performed equally well with a less than 24 hours of hospitalization. Elmore JM, Kirsch AJ, Perez – Brayfield MR, HC Scherz, Koyle MA.

The report is based on data available in the literature, with higher quality studies, supporting the role of these nutrients on bone health. Vitamin D deficiency is to encounter a major health problem, as it to to the pathogenesis of osteoporosis and hip fractures and other skeletal and non-skeletal disorders.. In April this year, IOF published global recommendations for vitamin D in older adults*, which advised higher daily intakes in this age group from 800 to 1000 IU / day.Said target said neutral sphingomyelinase is a protein where is activated, a chain of reactions at the cell, which can neuronal death neuronal death and memory loss. The results of the study NIH and the Alzheimer’s Association funded in the 22 September edition of the Journal of Neuroscience published. – ‘It are several neurotoxicity neurotoxic, disease-causing pathways to the to neutral sphingomyelinase, the loss of nerve cells in the brains of an Alzheimer patient,’said Kalipada Pahan, neurological scientists and principal investigator in Rush. ‘If we can stop the activation the neutral sphingomylinase be able can stop in a position , loss of memory and progression of Alzheimer ‘s disease. ‘.. ‘s disease. A new destination for Alzheimer’s diseaseNeurological explorer Rush University Medical Center who a new therapeutic target of potentially potentially leading to a new way to prevent the progression of Alzheimer’s disease find.

The results from this study is very promising and our next step towards It is to translate this knowledge in which clinic. If we may developing and test a clinical medications that can align neutral sphingomyelinase, we will to to be able stopping amnesia in Alzheimer’s patients, said Pahan.. At Rush explorer Been able determine that the neutral sphingomyelinase triggered by the activated brain cells and beta – amyloid. However, when the neutral sphingomyelinase using of a small molecule inhibitor and a chemical inhibitor, thinking skills, activated brain cell and beta-amyloid was inhibited could kill the neurones.

Expert tested the two inhibitors with human brain cells into a mouse model and cell culture model.